Non‐selective beta‐blocker is associated with reduced mortality in critically ill patients with cirrhosis: A real‐world study

Abstract

SummaryBackgroundApart from direct portal pressure reduction, non‐selective beta‐blockers (NSBB) modulate inflammatory response, which could be beneficial in patients with acute decompensation (AD). We therefore aimed to evaluate the effect of NSBB on 28‐day mortality and markers of systemic inflammation in a propensity score‐matched (PSM) cohort of AD patients requiring intensive care unit (ICU) admission.MethodsPatients were recruited from registry of AD patients requiring ICU admission. Out of total 445 patients, 108 patients on NSBB before admission (NSBB use group) were PSM for age, gender, pre‐admission Child–Turcotte–Pugh score and history of previous decompensation to 108 patients not on NSBB (non‐NSBB use group) which served as the control group. ICU parameters, markers of systemic inflammation and 28‐day mortality were compared by standard statistical tests.ResultsAfter PSM, no difference was observed in aetiology of cirrhosis, or precipitating event for AD between the groups. Pre‐admission creatinine, bilirubin, international normalised ratio and haemoglobin were similar between the groups, whereas pre‐admission white cell count (WCC) and neutrophil to lymphocyte ratio (NLR) was lower in NSBB‐group. On admission to ICU, NSBB group had lower heart rate (p = 0.006), platelets (p = 0.012), WCC (p = 0.006), NLR (p = 0.039) and C‐reactive protein (p = 0.007). Significantly more community acquired bacterial infections (p = 0.006), renal failure (p = 0.033) and higher grades of acute‐on‐chronic liver failure (ACLF; p = 0.012) were observed in non‐NSBB group. Significantly lower 28‐day (p = 0.001) and 90‐day (p = 0.002) mortality was seen in NSBB group. Univariate and multivariable analysis for 28‐day mortality showed that while ACLF at presentation and community acquired bacterial infection were independent negative predictors, prior NSBB use was positive predictors of survival.ConclusionsPrior use of NSBB is associated with improved 28‐ and 90‐day mortality in critically ill cirrhosis patients with AD which is mediated probably by blunting of the inflammatory response.